Glaxosmithkline Pharmaceuticals profit and loss

Latest FY26

Revenue: ₹3,822cr+1.9% on FY25
EBITDA: ₹1,309cr+11.2% on FY25
Net profit: ₹1,036cr+11.7% on FY25
EPS: ₹54.520.0% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	3,955	3,822	3,749	3,454	3,252	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	145	145	146	123	101
	4,100	3,967	3,895	3,576	3,352
	381	436	500	545	427
	1,057	910	845	853	788
	−46.8	4.5	45.9	−63.7	69.0
	614	607	580	624	595
	3.3	2.7	1.3	1.8	1.8
	66.8	66.4	66.8	69.7	65.8
	596	554	601	586	568
	2,671	2,582	2,640	2,617	2,515
	1,354	1,309	1,177	909	804
	1,287	1,243	1,111	839	739
Profit
	1,429	1,385	1,255	960	837
	20.6	20.6	4.7	−144	−1.0
	1,449	1,406	1,260	816	836
	369	361	326	238	247
	12.7	9.5	6.3	−11.4	−18.4
	381	370	332	226	229
	1,068	1,036	928	590	611
	1,068	1,036	928	590	608
	0.0	0.0	0.0	0.0	3.1
	−7.5	−7.5	−2.7	−4.2	−6.0
	1,061	1,028	925	586	605
	—	—	928	590	611
Per share
	₹62.01	₹54.52	₹54.52	₹34.83	₹36.05
	₹63.05	₹54.76	₹54.76	₹34.83	₹36.05
Continuing & discontinued operations
	0.0	0.0	0.0	0.0	4.1
	0.0	0.0	0.0	0.0	1.1
Other comprehensive income — detail
	—	−7.5	−2.7	—	—
	—	−10.0	−3.6	−5.6	−8.1
	—	−2.4	−0.9	—	—
	—	—	—	−1.4	−2.0
	—	—	928	586	605
Per share — as-filed variants
	₹62.01	₹54.52	₹54.52	₹34.83	₹35.87
	₹63.05	₹54.76	₹54.76	₹34.83	₹35.87
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.18
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.18
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	2,564	2,471	2,358	2,119	1,967
	64.8%	64.6%	62.9%	61.4%	60.5%
Adjusted (ex-exceptional items) — derived
	1,429	1,385	1,255	960	837
	20.6	20.6	4.7	−144	−1.0
	1,053	1,021	924	694	611
	₹61.13	₹53.72	₹54.32	₹40.96	₹36.09

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLAXO₹2,498.00

Glaxosmithkline Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersPFIZER ABBOTINDIA MEDANTA ANTHEM AJANTPHARM IPCALAB GLENMARK BIOCONMcap ₹42,319 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	3,251.7	3,453.7	3,749.2	3,821.7	3,954.9
Other Income	100.7	122.6	145.9	145.4	145.4
Total Income	3,352.4	3,576.3	3,895.1	3,967.0	4,100.3
Expenses
+ Cost of Materials Consumed	427.5	545.2	499.9	436.2	381.0
+ Purchases of Stock-in-Trade	788.4	853.1	845.1	910.5	1,057.0
+ Changes in Inventories	69.0	-63.7	45.9	4.5	-46.8
+ Employee Benefit Expense	595.0	624.4	579.7	607.3	613.7
+ Finance Costs	1.8	1.8	1.3	2.7	3.3
+ Depreciation & Amortisation	65.8	69.7	66.8	66.4	66.8
+ Other Expenses	567.6	586.1	601.3	554.2	596.4
Total Expenses	2,515.0	2,616.5	2,640.0	2,581.6	2,671.5
EBITDA	804.3	908.7	1,177.4	1,309.2	1,353.5
EBIT	738.5	839.0	1,110.6	1,242.8	1,286.7
Profit
PBT before Exceptional Items	837.4	959.8	1,255.2	1,385.4	1,428.9
+ Exceptional Items	-1.0	-143.6	4.7	20.6	20.6
Pretax Income	836.4	816.2	1,259.9	1,406.0	1,449.5
+ Current Tax	247.1	237.6	326.0	360.6	368.6
+ Deferred Tax	-18.4	-11.4	6.3	9.5	12.7
Tax Expense	228.8	226.2	332.3	370.0	381.3
Net Income	610.7	590.0	927.6	1,036.0	1,068.2
+ Net Income — Continuing Ops	607.6	590.0	927.6	1,036.0	1,068.2
+ Net Income — Discontinued Ops	3.1	0.0	0.0	0.0	0.0
+ Other Comprehensive Income	-6.0	-4.2	-2.7	-7.5	-7.5
Total Comprehensive Income	604.7	585.8	924.9	1,028.4	1,060.6
Net Income to Common	610.7	590.0	927.6	—	—
Per Share
Basic EPS	36.05	34.83	54.52	54.52	62.01
Diluted EPS	36.05	34.83	54.76	54.76	63.05
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	4.1	0.0	0.0	0.0	0.0
+ Tax — Discontinued Operations	1.1	0.0	0.0	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-2.7	-7.5	—
+ Items NOT to be Reclassified to P&L	-8.1	-5.6	-3.6	-10.0	—
+ Tax on Items NOT to be Reclassified	—	—	-0.9	-2.4	—
+ Tax on Items NOT to be Reclassified — alt tag	-2.0	-1.4	—	—	—
Comprehensive Income — Owners of Parent	604.7	585.8	927.6	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	35.87	34.83	54.52	54.52	62.01
Diluted EPS — Continuing Operations	35.87	34.83	54.76	54.76	63.05
Basic EPS — Discontinued Operations	0.18	0.00	0.00	0.00	0.00
Diluted EPS — Discontinued Operations	0.18	0.00	0.00	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,966.9	2,119.2	2,358.4	2,470.6	2,563.7
Gross Margin %	60.49	61.36	62.90	64.65	64.82
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	837.4	959.8	1,255.2	1,385.4	1,428.9
− Exceptional Items (reconciliation)	-1.0	-143.6	4.7	20.6	20.6
Net Income Adj (tax-effected)	611.4	693.8	924.1	1,020.8	1,053.0
EPS Adj	36.09	40.96	54.32	53.72	61.13
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	169.4	169.4	169.4	169.4	169.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.